PLUR Pluri Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1158780 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY10.0%
TTM net income YoY-25.8%
TTM EPS YoY15.7%
Revenue 3-yr CAGR79.1%
Net income 3-yr CAGR—
Margins
Gross margin52.0%
Operating margin-2,341.1%
Net margin-1,943.9%
FCF margin-1,317.8%
EBITDA margin-2,306.0%
Returns
ROE—
ROA-96.8%
ROIC (approx.)—
Asset turnover0.05x
Leverage & solvency
Liabilities / assets167.1%
Debt / equity—
Current ratio0.27x
Interest coverage-36.77x
Cash quality & payout
Operating cash flow / net income0.66x
Accruals ratio-33.0%
Payout ratio—
Capex / revenue35.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | $1.02M | $1.34M |
| Cost of revenue | $563,000 | $682,000 |
| Gross profit | $453,000 | $654,000 |
| R&D expense | $15.09M | $12.85M |
| SG&A expense | $10.30M | $9.98M |
| Operating income | -$24.94M | -$22.18M |
| Interest expense | $932,000 | $873,000 |
| Pretax income | -$25.39M | -$23.25M |
| Income tax | -$25,000 | -$5,000 |
| Net income | -$23.82M | -$22.58M |
| EBITDA | -$24.43M | -$21.86M |
| EPS (basic) | -2.44 | -3.56 |
| EPS (diluted) | -2.44 | -3.56 |
| Weighted avg. shares (diluted) | 9.74M | 6.34M |
| Balance sheet | ||
| Cash & equivalents | $3.53M | $7.20M |
| Current assets | $8.73M | $22.09M |
| PP&E, net | $1.57M | $1.82M |
| Goodwill | $3.14M | $3.14M |
| Intangibles | $2.61M | $2.79M |
| Total assets | $24.88M | $38.68M |
| Current liabilities | $32.72M | $32.33M |
| Total liabilities | $42.31M | $39.55M |
| Shareholders' equity | -$23.04M | -$6.84M |
| Shares outstanding | 10.82M | 7.89M |
| Cash flow statement | ||
| Operating cash flow | -$19.59M | -$18.21M |
| Capital expenditure | $633,000 | $1.62M |
| Free cash flow | -$20.22M | -$19.83M |
| Investing cash flow | $9.90M | $8.03M |
| Financing cash flow | $7.04M | $9.53M |
| Depreciation & amortization | $511,000 | $316,000 |
| Stock-based compensation | $3.73M | $2.14M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.